Skip to main content

Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction.

Coene J, Devreese K, Sabot B, Feys HB, Vandekerckhove P, Compernolle V

Publication: Transfusion (2014) • Vol 54(5) • Page 1321-31PMID: 24472023View on PubMed

Purpose

The purpose of this paper was to determine the effects of three different pathogen reduction treatments on levels of coagulation factors and coagulation test results in plasma.

Conclusion

Prior to pathogen reduction, levels of all analytes were comparable between treatment groups. Methylene blue (MB), riboflavin (RF) and Amotasalen (AS) treatments reduced levels of fibrinogen, factors (F) II, V, VIII, IX, and XI, Protein C and Protein S and increased prothrombin time (PT) and activated partial thromboplastin time (APTT), but antithrombin was only reduced in RF- and AS-treated specimens, and changes in thrombin generation (TG) depended on treatment. Endogenous thrombin potential (ETP) declined with all treatments while peak thrombin declined in RF- and AS-treated specimens and increased in MB-treated specimens. Lag time and time to peak were shortened by MB and AS treatments but prolonged after RF treatments. The reductions in fibrinogen, FII, FV, FVIII, FIX, FXI and Protein C and changes in PT, APTT, lag time, peak thrombin and ETP were largest for RF-treated specimens.

Studies (1)

Purpose

The purpose of this study was to determine the effects of three different pathogen reduction treatments on levels of coagulation factors and coagulation test results in plasma. Plasma was obtained from citrate phosphate dextrose (CPD) blood that had been left overnight at room temperature. Plasma was frozen and stored at -35 degrees C for 1-8 days. Plasma was then thawed in a 35 degrees C water bath and subjected to the various experimental treatments. For MB and RF treatment, the average specimen volume was 254 mL, but for AS treatment, the average specimen volume was 530 mL. After treatment, plasma was frozen in cryovials and stored at -80 degrees C until analysis.

Summary of Findings

Prior to pathogen reduction, levels of all analytes were comparable between treatment groups. MB, RF and AS treatments reduced levels of fibrinogen, FII, FV, FVIII, FIX, FXI, Protein C and Protein S (p<0.01, all) and increased PT and APTT, but antithrombin was only reduced in RF- and AS-treated specimens (p<0.01, both), and changes in TG depended on treatment. ETP declined with all treatments, while peak thrombin declined in RF- and AS-treated specimens and increased in MB-treated specimens. Lag time and time to peak were shortened by MB and AS treatments but prolonged after RF treatments. The reductions in fibrinogen, FII, FV, FVIII, FIX, FXI and Protein C and changes in PT, APTT, lag time, peak thrombin and ETP were largest for RF-treated specimens. The reductions in FII, FVIII, FIX, PC, and AT were smallest in MB-treated specimens, and the reductions in FV and FXI were smallest in AS-treated specimens. The percent recoveries of FV and FIX were lowest in RF-treated specimens, and the percent recoveries of fibrinogen, FII, Protein C, Protein S, and antithrombin were lowest for MB-treated specimens. The highest percent recoveries of fibrinogen, FV, FXI, and PC were found after AS treatment, and the highest recoveries of PS and AT were observed after treatment with RF.
  • Biospecimens

    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    Not specified
  • Platforms

    GlycoproteinFlow cytometry
    GlycoproteinColorimetric assay
    ProteinHematology/ auto analyzer
    ProteinImmunoassay
    ProteinColorimetric assay
    MorphologyHematology/ auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsAliquot size/volume
    254 mL
    530 mL
    Biospecimen Aliquots and ComponentsBlood processing method
    Amotasalen
    Methylene blue
    Riboflavin
    Untreated